#AANAM – Onpattro Reduced Nervous System Damage in Trial

#AANAM – Onpattro Reduced Nervous System Damage in Trial

292988

#AANAM – Onpattro Reduced Nervous System Damage in Trial

Editor’s note: The FAP News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read more stories from the conference. Treatment with Onpattro (patisiran) lessened signs of nervous system damage in people with familial amyloid polyneuropathy (FAP), new clinical trial data suggests. Findings from a separate analysis also indicated the safety and efficacy of Onpattro are not affected by concurrent or prior treatment with transthyretin stabilizers, a different…

You must be logged in to read/download the full post.